Please use this identifier to cite or link to this item: https://dspace.uzhnu.edu.ua/jspui/handle/lib/10803
Full metadata record
DC FieldValueLanguage
dc.contributor.authorГотько, Євген Степанович-
dc.contributor.authorTamás Pintera-
dc.contributor.authorZandra Klippel-
dc.contributor.authorAlvydas Cesas-
dc.contributor.authorAdina Croitoru-
dc.contributor.authorJochen Decaestecker-
dc.contributor.authorPeter Gibbs-
dc.contributor.authorJacek Jassem-
dc.contributor.authorGalina Kurteva-
dc.contributor.authorJan Novotny-
dc.contributor.authorSeamus O’Reilly-
dc.contributor.authorTomas Salek-
dc.contributor.authorMaureen Reiner-
dc.date.accessioned2016-11-28T09:35:03Z-
dc.date.available2016-11-28T09:35:03Z-
dc.date.issued2013-
dc.identifier.urihttps://dspace.uzhnu.edu.ua/jspui/handle/lib/10803-
dc.language.isoenuk
dc.subjectPegfilgrastim, colorectal cancer, febrile neutropenia, overall survivaluk
dc.titleA Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the PAVES Studyuk
dc.typeTextuk
dc.pubTypeСтаттяuk
Appears in Collections:Наукові публікації кафедри радіології та онкології

Files in This Item:
File Description SizeFormat 
Abstract.PDF302.54 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.